FDA Approves NPS Gattex for Injection for Some SBS Patients
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that the U.S. Food and Drug Administration (FDA) has approved Gattex® (Teduglutide [rDNA origin]) for Injection, for subcutaneous use for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. Gattex will be available in the first quarter of 2013. For full prescribing information, please visit www.Gattex.com.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.